Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 9.63B 8.42B 7.77B 7.17B 13.61B 918B 13.84B 92.8B 36.44B 452B 36.14B 35.36B 1,555B P/E 2026 *
-16.2x
P/E 2027 * -33.4x
Enterprise Value 9.37B 8.2B 7.56B 6.99B 13.25B 894B 13.48B 90.36B 35.49B 440B 35.2B 34.43B 1,514B EV / Sales 2026 *
10.5x
EV / Sales 2027 * 6.75x
Free-Float
99.09%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ionis Pharmaceuticals, Inc.

1 day-9.37%
1 week-28.79%
Current month-26.54%
1 month-20.55%
3 months-22.51%
6 months-27.46%
Current year-26.37%
1 week 58.2
Extreme 58.2
86.74
1 month 58.2
Extreme 58.2
86.74
Current year 58.2
Extreme 58.2
86.74
1 year 40.03
Extreme 40.03
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.9
Extreme 23.9
86.74
Manager TitleAgeSince
Investor Relations Contact 60 2012-06-30
Chief Executive Officer 64 2019-12-31
Director of Finance/CFO 64 2000-04-30
Director TitleAgeSince
Director/Board Member 64 2005-12-12
Director/Board Member 73 2002-04-30
Director/Board Member 64 2019-03-24
Date Insider Type Main position Quantity % Market Cap.
06-30Free

Director

7,670 0.0046%
06-30Free

Director

7,670 0.0046%
06-30Fiscal year

Director

42,224 0.0255%
Change 5-day change 1-year change 3-year change Capi.($)
-9.37%-28.79%+37.45%+39.42% 9.63B
+0.58%+2.06%+2.92%+10.86% 50.73B
-2.22%-1.25%+385.40%+586.81% 39.73B
-0.54%+0.39%+25.57%-5.28% 34.69B
-1.36%+0.35%+17.88%+55.14% 33.21B
+1.21%-4.58%+3.00%+35.46% 26.76B
-1.81%-1.48% - - 16.8B
+0.51%-3.47%+63.97%+122.60% 15.37B
+0.23%-0.58%+13.76%+21.11% 13.78B
-0.62%-3.09%+10.29%-31.35% 12.85B
Average -1.34%-3.63%+62.25%+92.75% 25.35B
Weighted average by Cap. -0.82%-1.32%+78.93%+120.87%

Financials

2026 *2027 *
Net sales 889M 778M 717M 663M 1.26B 84.8B 1.28B 8.57B 3.37B 41.78B 3.34B 3.27B 144B 1.41B 1.24B 1.14B 1.05B 2B 135B 2.03B 13.62B 5.35B 66.39B 5.31B 5.19B 228B
Net income -594M -519M -479M -443M -840M -56.64B -854M -5.73B -2.25B -27.9B -2.23B -2.18B -95.93B -292M -255M -235M -217M -413M -27.83B -420M -2.81B -1.1B -13.71B -1.1B -1.07B -47.14B
Net Debt -252M -221M -204M -188M -357M -24.08B -363M -2.43B -956M -11.86B -948M -927M -40.78B -86.16M -75.36M -69.51M -64.2M -122M -8.22B -124M -831M -326M -4.05B -323M -316M -13.92B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,402
Date Price Change Volume
26-07-10 US$58.25 -9.37% 11,444,106
26-07-09 US$64.27 -23.90% 20,447,626
26-07-08 US$84.46 -2.17% 2,280,833
26-07-07 US$86.33 +3.79% 2,646,707
26-07-06 US$83.18 +1.69% 1,847,437
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
58.25USD
Average target price
93.45USD
Spread / Average Target
+60.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock